All In Biotech

Drug Trial Radar · NCT00803686

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

A Randomized, Open-Label, Placebo-Controlled, Two-Period Crossover Study of the Effect on CTx-1 Concentrations of a Single 200 μg Recombinant Salmon Calcitonin (rsCT) Dose Given at Night to Normal, Healthy, Postmenopausal Women

Last checked: Nov 20, 2026Latest source record: Jun 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Dec 2008

Primary completion

Jan 2009

Study completion Jan 2009

Sponsor

Lead sponsor
Tarsa Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Female only, from 45 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being conducted to assess the plasma CTx-1 concentrations when dosing is at night and to compare these results with those obtained with a placebo control and with commercially available nasal calcitonin.

Conditions

  • Phase 1 Pharmacodynamic Study

Interventions

  • Oral rsCT tabletDrug

    On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.

  • Oral Placebo TabletDrug

    Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.

  • Oral rsCT tabletDrug

    Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.

  • Fortical (rsCT) nasal sprayDrug

    Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacodynamic Effect of Oral CalcitoninTime frame: 12 hr

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bio-Kinetic Clinical Applications, Inc.

    Springfield, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.